Articles | Volume 8, issue 6
https://doi.org/10.5194/jbji-8-219-2023
https://doi.org/10.5194/jbji-8-219-2023
Original full-length article
 | 
30 Oct 2023
Original full-length article |  | 30 Oct 2023

Antimicrobial prophylaxis with teicoplanin plus gentamicin in primary total joint arthroplasty

Tariq Azamgarhi, Craig Gerrand, John A. Skinner, Alexander Sell, Robert A. McCulloch, and Simon Warren

Viewed

Total article views: 1,061 (including HTML, PDF, and XML)
HTML PDF XML Total BibTeX EndNote
766 196 99 1,061 81 81
  • HTML: 766
  • PDF: 196
  • XML: 99
  • Total: 1,061
  • BibTeX: 81
  • EndNote: 81
Views and downloads (calculated since 30 Oct 2023)
Cumulative views and downloads (calculated since 30 Oct 2023)

Viewed (geographical distribution)

Total article views: 1,025 (including HTML, PDF, and XML) Thereof 1,025 with geography defined and 0 with unknown origin.
Country # Views %
  • 1
1
 
 
 
 

Cited

Latest update: 23 Apr 2025
Download
Short summary
We compared prosthetic joint infection (PJI) and acute kidney injury (AKI) rates among cohorts before and after changing our hospital's antimicrobial prophylaxis from cefuroxime to teicoplanin plus gentamicin for primary total joint arthroplasty. Switching to teicoplanin and gentamicin was associated with a significant risk reduction for PJI of 75.2 %. Significantly higher AKI rates were seen in patients receiving teicoplanin plus gentamicin; however, these were mild (KDIGO stage 1).
Share